India's CDMO market set to double by 2028, driven by API strength, cost advantages, and global demand diversification.

Lupin: Drug manufacturer Lupin Ltd. received tentative approval from the U.S. FDA for its generic version of a combination ...

Broader markets outperformed the benchmarks, with small-cap shares leading the charge, as the Nifty Smallcap100 index ended ...